FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HCT Type (check all that apply): 

 
 

gfedcb
Autologous

 
 

 
gfedcb

Allogeneic, unrelated

 
 

 
gfedcb

Allogeneic, related

 

Product type: (check all that apply) 

 
 

gfedcb
Bone marrow

 
 

 
gfedcb

PBSC

 
 

 
gfedcb

Single cord blood unit

 
 

 
gfedcb

Multiple cord blood units

 
 

 
gfedcb

Other product

 
 
Specify:    

 
 

Visit

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 

Specify:

     

 
 

1  Was the recipient transplanted for or do they have a history of amyloidosis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

2  Did the recipient have features of multiple myeloma?

    
 nmlkji

yes  
 nmlkji

no  

  Key Fields 

  Disease Specificity Questions: 1 - 2

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 14



 
3  Compared to the disease status prior to the preparative regimen, what was the best response to HCT since the date of the last report?

    (Include response to any therapy given for post-HCT maintenance or consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease.)   

 nmlkji
Stringent 

complete 

remission 

(sCR)  

—CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence 
(confirmation with repeat bone marrow biopsy not needed).  (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by 
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an 

abnormal clone is Κ/λ of > 4:1 or < 1:2.)  sCR requires two consecutive assessments made at any time before the institution of any new therapy, and no known 
evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR requirements.  

 nmlkji
Complete 

remission 

(CR)  

— negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in the bone marrow 
(confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution of any new 
therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy CR 

requirements.  

 nmlkji
Near complete 

remission (nCR)  

— serum & urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); ≤ 5% plasma cells in bone 
marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of progressive or 
new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements.  

 nmlkji
Very good partial 

remission (VGPR)  

— serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein and urine M-protein level < 
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of 
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.  

 nmlkji
Partial 

remission 

(PR)  

— ≥ 50% reduction in serum M-protein, and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M-protein are 
unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein ≥ 1 g/dL.   Urine M-protein ≥ 200 mg/24 hours • serum free light chain assay shows 
involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and uninvolved free light chain 
levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a ≥ 50% 
reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was ≥ 30%. In addition to the above listed 
criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.  PR requires two consecutive assessments made at any 
time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic 

studies are not required to satisfy PR requirements.  

 nmlkji
Stable 

disease (SD)  

— not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy, and 
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD 

requirements.  

 nmlkji
Progressive 

disease (PD)  

— requires any one or more of the following:  Increase of ≥ 25% from the lowest value achieved in:  serum M-component with an absolute increase ≥ 0.5 g/dL 
(for progressive disease, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M-component is ≥ 5 g/dL); and/or urine M-
component with an absolute increase ≥ 200 mg.24 hours; and/or for recipients without measurable serum and urine M-protein levels: the difference between 
involved and uninvolved free light chain levels with an absolute increase > 10 mg/dL; and/or bone marrow plasma cell percentage with absolute percentage ≥ 
10% (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse); and/or definite development of new bone lesions or soft tissue plasmacytomas, 

or definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium > 11.5 
mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder PD requires two consecutive assessments made at any time before 

classification as disease progression, and/or the institution of any new therapy.  

 nmlkji
Relapse from CR 

(Rel) (untreated)  

— requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis, development of ≥ 5% plasma cells 
in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g., new 

plasmacytoma, lytic bone lesion, hypercalcemia)  Rel requires two consecutive assessments made at any time before classification as relapse, and/or the 
institution of any new therapy.  

 
 

4  Was the date of best response previously reported?

    
 nmlkji

yes  
 nmlkji

no  

 
 
5  Date assessed: __ __ __ __ - __ __- __ __  

 

Laboratory studies at the time of best response to HCT 
 

6  Plasma cells in bone marrow aspirate

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
7     % 

 
 

8  Plasma cells in bone marrow biopsy

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
9     % 

 
 

10  Serum monoclonal protein (M-spike) (only from electrophoresis)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

  
 
11     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

12  Serum immunofixation

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

Disease Assessment at the Time of Best Response to HCT Questions: 3 - 34

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 14



 
 

13  Specify monoclonal immunoglobulin result

    
 nmlkji

Present  
 nmlkji

Absent  

 

Specify bands currently present: 
 

14  Original monoclonal bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

15  New monoclonal (or oligoclonal) bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

16  Total urinary protein excretion

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
17     g/24 hours 

 
 

18  Urinary monoclonal protein (M-spike)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 
19     mg/24 hours 

 
 

20  Urinary immunofixation

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

21  Specify monoclonal immunoglobulin result

    
 nmlkji

Present  
 nmlkji

Absent  

 

Specify bands currently present: 
 

22  Original monoclonal bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

23  New monoclonal (or oligoclonal) bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

24  Serum free light chains - κ(kappa)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

  
 
25     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
26  Upper limit of normal for κ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 
 

27  Serum free light chains — λ (lambda)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

  
 
28     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
29  Upper limit of normal for λ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 
 

30  Was the disease status assessed by cytogenetic testing (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

31  Was the disease status assessed via FISH?

    
 nmlkji

yes  
 nmlkji

no  

 
 
32  Date assessed: __ __ __ __ - __ __- __ __  

 
 

33  Was the disease status assessed via conventional cytogenetics?

    
 nmlkji

yes  
 nmlkji

no  

 
 
34  Date assessed: __ __ __ __ - __ __- __ __  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 14



Complete questions 35-60 for Amyloid patients only.  If diagnosis was other than amyloidosis or there is no history of it, continue with question 61. 
 

Specify the recipient’s best response to the HCT for each of the following hematologic and organ systems: 
 

Hematologic (Immunochemical)  
 

 
35  Specify the recipient’s best hematologic response to the HCT

    
 nmlkji

Complete response 

(CR)  

 — requires all of the following: • serum and urine negative for monoclonal proteins by immunofixation • normal free light chain ratio • plasma cells in 
marrow < 5%  

 nmlkji
Partial response 

(PR)  

 — requires any of the following: • ≥ 50% reduction in current serum monoclonal protein levels > 0.5 g/dL • ≥ 50% reduction in current urine light chain levels 
> 100 mg/day with a visible peak • ≥ 50% reduction in current free light chain levels > 10 mg/dL  

 nmlkji
No response (NR) / stable disease (SD)   — does not meet criteria for CR, PR nor progressive disease 

 nmlkji
Progressive 

disease  

 — requires any of the following: • if progressing from CR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must double) • if 
progressing from PR or SD, ≥ 50% increase in serum M-protein to > 0.5 g/dL, or ≥ 50% increase in urine M-protein to > 200 mg/day with visible peak present • 
free light chain increase of ≥ 50% to > 10 mg/dL (100 mg/L)  

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

36  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
37  __ __ __ __ - __ __- __ __  

 

Cardiac 

 
 

38  Specify the recipient’s best cardiac response to the HCT

    
 nmlkji

Cardiac 

response  

— requires any of the following: • ≥ 2 mm decrease in mean interventricular septal wall thickness by echocardiogram • ≥ 20% increase in left ventricular ejection 
fraction • ≥ 2 grade decrease in New York Heart Association functional class without an increase in diuretic use and no increase in wall thickness • reduction 
(≥30% and ≥300 ng/L) of NT-proBNP in patients in whom the eGFR is ≥45 mL/minute/1.73 m^2  

 nmlkji
No response / stable disease  — does not meet criteria for cardiac response nor progressive disease 

 nmlkji
Progressive 

disease  

— requires any of the following: • ≥ 2 mm increase from baseline in interventricular septal wall thickness by echocardiogram • ≥ 10% decrease in left 
ventricular ejection fraction • ≥ 1 grade increase in New York Heart Association functional class  

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

39  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
40  __ __ __ __ - __ __- __ __  

 
 

41  Was there clinical improvement in GI involvement in response to the HCT?

    (decrease in diarrhea)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

42  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
43  __ __ __ __ - __ __- __ __  

  Hematologic and Organ Parameters at the Time of Best Response (for Amyloid Patients Only) Questions: 35 - 60

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 14



 

Hepatic 

 
 

44  Specify the recipient’s best hepatic response to the HCT

    
 nmlkji

Hepatic 

response  

— requires all of the following: • ≥ 2 cm decrease in liver span if hepatomegaly present (liver span > 15 cm) • ≥ 50% decrease and/or normalization of serum 
alkaline phosphatase level  

 nmlkji
No response / stable disease  — does not meet criteria for hepatic response nor progressive disease 

 nmlkji
Progressive disease  — requires the following: • ≥ 50% increase in serum alkaline phosphatase level 

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

45  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
46  __ __ __ __ - __ __- __ __  

 

 

Autonomic Nervous 

 
 

47  Specify the best response of autonomic neuropathy to the HCT

    
 nmlkji

Autonomic neuropathy response  — resolution of symptomatic orthostatic hypotension 

 nmlkji
No response / stable disease  — does not meet criteria for autonomic neuropathy response nor progressive disease 

 nmlkji
Progressive disease  — worsening of symptomatic orthostatic hypotension not attributable to medications or blood volume depletion 

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

48  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
49  __ __ __ __ - __ __- __ __  

 
50  Specify the best response of peripheral neuropathy to the HCT

    
 nmlkji

Peripheral neuropathy response  — requires any of the following: • resolution of abnormal physical findings • resolution or improvement of abnormal EMG and/or NCV 
findings  

 nmlkji
No response / stable disease  — does not meet criteria for peripheral neuropathy response nor progressive disease 

 nmlkji
Progressive disease  — requires any of the following: • worsening of physical findings • worsening of EMG and/or NCV findings 

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

51  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
52  __ __ __ __ - __ __- __ __  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 14



 

Renal 

 
 

53  Specify the recipient's best renal response to the HCT

    
 nmlkji

Renal 

response  

— ≥ 50% decrease of at least 0.5 g/day in 24 hour urine protein of > 0.5 g/day pre-treatment – creatinine and creatinine clearance must not have worsened by 
≥ 25% over baseline  

 nmlkji
No response / stable disease  — does not meet criteria for renal response nor progressive disease 

 nmlkji
Progressive 

disease  

— requires any of the following: • ≥ 50% increase of at least 1 g/day for urine protein to > 1 g/day • 25% worsening of serum creatinine or creatinine 
clearance  

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

54  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
55  __ __ __ __ - __ __- __ __  

 

 

Other system 

 
 

56  Did any other system respond to the HCT?

    
 nmlkji

yes  
 nmlkji

no  

 
 
57  Specify other system:    

 
 

58  Specify best response to HCT for this system

    
 nmlkji

Response  

 nmlkji
No response / stable disease  

 nmlkji
Progressive disease  

 nmlkji
Not applicable  

 
 

59  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Previously reported  

 
 
60  __ __ __ __ - __ __- __ __  

 
 

61  Was therapy given since the date of the last report for reasons other than relapse or progressive disease?

    (Include any maintenance and consolidation therapy.)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 

Line of Therapy 

 
 

62  Systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
64  Date started: __ __ __ __ - __ __- __ __  

 
 

65  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
66  Date stopped: __ __ __ __ - __ __- __ __  

  Post-HCT Therapy Questions: 61 - 101

  Line of Therapy (1) Questions: 62 - 99 

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 14



 
 

67  Number of cycles

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
68  Number of cycles:    

 
 

69  Bortezomib (Velcade)

    
 nmlkji

yes  
 nmlkji

no  

 
 

70  Carfilzomib

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  Carmustine (BCNU, Gliadel)

    
 nmlkji

yes  
 nmlkji

no  

 
 

72  Cisplatin (Platinol, CDDP)

    
 nmlkji

yes  
 nmlkji

no  

 
 

73  Clarithromycin (Biaxin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

74  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 
 

75  Cyclophosphamide (Cytoxan)

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  Cytarabine (Ara-C)

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Doxorubicin (Adriamycin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Doxorubicin liposomal (Doxil)

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Idarubicin (Idamycin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Interferon-α (Intron, Roferon) (includes PEG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

82  Lenalidomide (Revlimid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  Melphalan (L-PAM, Alkeran)

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  MLN 9708

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  Mitoxantrone (Novantrone)

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  Rituximab (Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 14



 
 

87  Thalidomide (Thalomid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  Vincristine (VCR, Oncovin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

89  Other systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
90  Specify other systemic therapy:    

 
 

91  Radiation therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 

93  Date started:

    __ __ __ __ - __ __- __ __  

 
 

94  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
95  Date stopped: __ __ __ __ - __ __- __ __  

 
96  Best response to line of therapy

    
 nmlkji

Stringent 

complete 

remission 

(sCR)  

—CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence 
(confirmation with repeat bone marrow biopsy not needed).  (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio 
by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence 

of an abnormal clone is Κ/λ of > 4:1 or < 1:2.)  sCR requires two consecutive assessments made at any time before the institution of any new therapy, 
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy 

sCR requirements.  

 nmlkji
Complete 

remission 

(CR)  

— negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in the bone 
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution 
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not 

required to satisfy CR requirements.  

 nmlkji
Near complete 

remission 

(nCR)  

— serum & urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); ≤ 5% plasma cells in 
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of 
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements.  

 nmlkji
Very good partial 

remission 

(VGPR)  

— serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein and urine M-protein 
level < 100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known 
evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR 

requirements.  

 nmlkji
Partial 

remission 

(PR)  

— ≥ 50% reduction in serum M-protein, and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M-protein are 
unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein ≥ 1 g/dL.   Urine M-protein ≥ 200 mg/24 hours • serum free light chain assay 
shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and uninvolved 
free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also 

unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was ≥ 
30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.  PR requires 
two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if 

radiographic studies were performed; radiographic studies are not required to satisfy PR requirements.  

 nmlkji
Stable 

disease (SD)  

— not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new 
therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to 

satisfy SD requirements.  

 nmlkji
Progressive 

disease (PD)  

— requires any one or more of the following:  Increase of ≥ 25% from the lowest value achieved in:  serum M-component with an absolute increase ≥ 0.5 
g/dL (for progressive disease, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M-component is ≥ 5 g/dL); and/or 
urine M-component with an absolute increase ≥ 200 mg.24 hours; and/or for recipients without measurable serum and urine M-protein levels: the 
difference between involved and uninvolved free light chain levels with an absolute increase > 10 mg/dL; and/or bone marrow plasma cell percentage 

with absolute percentage ≥ 10% (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse); and/or definite development of new bone 
lesions or soft tissue plasmacytomas, or definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of 
hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder PD requires 

two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.  

 nmlkji
Unknown  

 nmlkji
Not applicable  (Amyloidosis with no evidence of myeloma) 

 
 
97  Date response established: __ __ __ __ - __ __- __ __  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 14



 
 

98  Did disease relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 
99  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 
 

100  Has the disease relapsed or progressed since the date of last report?

    
 nmlkji

yes  
 nmlkji

no  

 
 
101  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 
 

102  Plasma cells in bone marrow aspirate

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
103     % 

 
 

104  Plasma cells in bone marrow biopsy

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
105     % 

 
 

106  Serum monoclonal protein (M-spike) (only from electrophoresis)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

  
 
107     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

108  Serum immunofixation

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

109  Specify monoclonal immunoglobulin result

    
 nmlkji

Present  
 nmlkji

Absent  

 

 

Specify bands currently present: 

 
 

110  Original monoclonal bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

111  New monoclonal (or oligoclonal) bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  Total urinary protein excretion

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 
113     g/24 hours 

 
 

114  Urinary monoclonal protein (M-spike)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 
115     mg/24 hours 

 
 

116  Urinary immunofixation

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

117  Specify monoclonal immunoglobulin result

    
 nmlkji

Present  
 nmlkji

Absent  

  Disease Status at the Time of Evaluation for This Reporting Period Questions: 102 - 136

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 14



 

Specify bands currently present: 
 

118  Original monoclonal bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

119  New monoclonal (or oligoclonal) bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

120  Serum free light chains - κ(kappa)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

  
 
121     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
122  Upper limit of normal for κ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 
 

123  Serum free light chains — λ (lambda)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

  
 
124     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
125  Upper limit of normal for λ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 
 

126  Was the disease status assessed by cytogenetic testing (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

127  Was the disease status assessed via FISH?

    
 nmlkji

yes  
 nmlkji

no  

 
 
128  Date assessed: __ __ __ __ - __ __- __ __  

 
 

129  Was disease detected?

    
 nmlkji

yes  
 nmlkji

no  

 
 

130  Was the status considered a disease relapse or progression?

    
 nmlkji

yes  
 nmlkji

no  

 
 

131  Was the disease status assessed via conventional cytogenetics?

    
 nmlkji

yes  
 nmlkji

no  

 
 
132  Date assessed: __ __ __ __ - __ __- __ __  

 
 

133  Was disease detected?

    
 nmlkji

yes  
 nmlkji

no  

 
 

134  Was the status considered a disease relapse or progression?

    
 nmlkji

yes  
 nmlkji

no  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 14



 
135  What was the disease status?

    
 nmlkji

Stringent 

complete 

remission 

(sCR)  

—CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence 
(confirmation with repeat bone marrow biopsy not needed).  (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by 
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an 

abnormal clone is Κ/λ of > 4:1 or < 1:2.)  sCR requires two consecutive assessments made at any time before the institution of any new therapy, and no 
known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR 

requirements.  

 nmlkji
Complete 

remission 

(CR)  

— negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in the bone marrow 
(confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution of any new 
therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy 

CR requirements.  

 nmlkji
Near complete 

remission (nCR)  

— serum & urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); ≤ 5% plasma cells in bone 
marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of progressive or 
new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements.  

 nmlkji
Very good partial 

remission 

(VGPR)  

— serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein and urine M-protein level < 
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of 
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.  

 nmlkji
Partial 

remission 

(PR)  

— ≥ 50% reduction in serum M-protein, and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M-protein are 
unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein ≥ 1 g/dL.   Urine M-protein ≥ 200 mg/24 hours • serum free light chain assay 
shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and uninvolved free 
light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, 

a ≥ 50% reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was ≥ 30%. In addition to the 
above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.  PR requires two consecutive 
assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies 

were performed; radiographic studies are not required to satisfy PR requirements.  

 nmlkji
Stable 

disease (SD)  

— not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy, 
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD 

requirements.  

 nmlkji
Progressive 

disease (PD)  

— requires any one or more of the following:  Increase of ≥ 25% from the lowest value achieved in:  serum M-component with an absolute increase ≥ 0.5 g/dL 
(for progressive disease, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M-component is ≥ 5 g/dL); and/or urine M-
component with an absolute increase ≥ 200 mg.24 hours; and/or for recipients without measurable serum and urine M-protein levels: the difference between 
involved and uninvolved free light chain levels with an absolute increase > 10 mg/dL; and/or bone marrow plasma cell percentage with absolute percentage ≥ 
10% (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse); and/or definite development of new bone lesions or soft tissue 

plasmacytomas, or definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum 
calcium > 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder PD requires two consecutive assessments made at 

any time before classification as disease progression, and/or the institution of any new therapy.  

 nmlkji
Relapse from CR 

(Rel) (untreated)  

— requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis, development of ≥ 5% plasma 
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g., 

new plasmacytoma, lytic bone lesion, hypercalcemia)  Rel requires two consecutive assessments made at any time before classification as relapse, 
and/or the institution of any new therapy.  

 nmlkji
Unknown  

 nmlkji
Not applicable  (Amyloidosis with no evidence of myeloma) 

 
 
136  Date assessed: __ __ __ __ - __ __- __ __  

Complete questions 137-162 for Amyloid patients only.  If diagnosis was other than amyloidosis or there is no history of it, continue with signature line. 
 

Specify the recipient’s current disease status for each of the following hematologic and organ systems: 
 

Hematologic (Immunochemical)  
 

 
137  Specify the recipient’s current hematologic status

    
 nmlkji

Complete response 

(CR)  

— requires all of the following: • serum and urine negative for monoclonal proteins by immunofixation • normal free light chain ratio • plasma cells 
in marrow < 5%  

 nmlkji
Partial response 

(PR)  

— requires any of the following: • ≥ 50% reduction in current serum monoclonal protein levels > 0.5 g/dL • ≥ 50% reduction in current urine light chain levels 
> 100 mg/day with a visible peak • ≥ 50% reduction in current free light chain levels > 10 mg/dL  

 nmlkji
No response (NR) / stable disease (SD)  — does not meet criteria for CR, PR nor progressive disease 

 nmlkji
Progressive 

disease  

— requires any of the following: • if progressing from CR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must double) • if 
progressing from PR or SD, ≥ 50% increase in serum M-protein to > 0.5 g/dL, or ≥ 50% increase in urine M-protein to > 200 mg/day with visible peak 
present • free light chain increase of ≥ 50% to > 10 mg/dL (100 mg/L)  

 nmlkji
Not assessed  

 nmlkji
Not applicable  

  Current Status of Amyloidosis for This Reporting Period (for Amyloid Patients Only) Questions: 137 - 162

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 14



 
 

138  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
139  __ __ __ __ - __ __- __ __  

 

Cardiac 

 
 

140  Specify the recipient’s current cardiac status

    
 nmlkji

Cardiac 

response  

— requires any of the following: • ≥ 2 mm decrease in mean interventricular septal wall thickness by echocardiogram • ≥ 20% increase in left ventricular 
ejection fraction • ≥ 2 grade decrease in New York Heart Association functional class without an increase in diuretic use and no increase in wall thickness • 
reduction (≥30% and ≥300 ng/L) of NT-proBNP in patients in whom the eGFR is ≥45 mL/minute/1.73 m^2  

 nmlkji
No response / stable disease  — does not meet criteria for cardiac response nor progressive disease 

 nmlkji
Progressive 

disease  

— requires any of the following: • ≥ 2 mm increase from baseline in interventricular septal wall thickness by echocardiogram • ≥ 10% decrease in left 
ventricular ejection fraction • ≥ 1 grade increase in New York Heart Association functional class  

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

141  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
142  __ __ __ __ - __ __- __ __  

 

 

Gastrointestinal 

 
 

143  Was there clinical improvement in GI involvement since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

144  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
145  __ __ __ __ - __ __- __ __  

 

Hepatic 

 
 

146  Specify the recipient’s current hepatic status

    
 nmlkji

Hepatic 

response  

— requires all of the following: • ≥ 2 cm decrease in liver span if hepatomegaly present (liver span > 15 cm) • ≥ 50% decrease and/or normalization of 
serum alkaline phosphatase level  

 nmlkji
No response / stable disease  — does not meet criteria for hepatic response nor progressive disease 

 nmlkji
Progressive disease  — requires any of the following: • ≥ 50% increase in serum alkaline phosphatase level 

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

147  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
148  __ __ __ __ - __ __- __ __  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 14



 

 

Autonomic Nervous 

 
 

149  Specify the current status of autonomic neuropathy

    
 nmlkji

Autonomic neuropathy response  — resolution of symptomatic orthostatic hypotension 

 nmlkji
No response / stable disease  — does not meet criteria for autonomic neuropathy response nor progressive disease 

 nmlkji
Progressive disease  — worsening of symptomatic orthostatic hypotension not attributable to medications or blood volume depletion 

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

150  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
151  __ __ __ __ - __ __- __ __  

 
152  Specify the current status of peripheral neuropathy

    
 nmlkji

Peripheral neuropathy 

response  

— requires any of the following: • resolution of abnormal physical findings • resolution or improvement of abnormal EMG and/or NCV 
findings  

 nmlkji
No response / stable disease  — does not meet criteria for peripheral neuropathy response nor progressive disease 

 nmlkji
Progressive disease  — requires any of the following: • worsening of physical findings • worsening of EMG and/or NCV findings 

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

153  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
154  __ __ __ __ - __ __- __ __  

 

Renal 

 
 

155  Specify the recipient’s current renal status

    
 nmlkji

Renal 

response  

— ≥ 50% decrease of at least 0.5 g/day in 24 hour urine protein of > 0.5 g/day pre-treatment – creatinine and creatinine clearance must not have worsened 
by ≥ 25% over baseline  

 nmlkji
No response / stable disease  — does not meet criteria for renal response nor progressive disease 

 nmlkji
Progressive 

disease  

— requires any of the following: • ≥ 50% increase of at least 1 g/day for urine protein to > 1 g/day • 25% worsening of serum creatinine or creatinine 
clearance  

 nmlkji
Not assessed  

 nmlkji
Not applicable  

 
 

156  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
157  __ __ __ __ - __ __- __ __  

 

 

Other system 

 
 

158  Was any other system assessed for current status?

    
 nmlkji

yes  
 nmlkji

no  

 
 
159  Specify other system:    

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 13 / 14



 
 

160  Specify the current status of this system

    
 nmlkji

Response  

 nmlkji
No response / stable disease  

 nmlkji
Progressive disease  

 nmlkji
Not applicable  

 
 

161  Date assessed

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
162  __ __ __ __ - __ __- __ __  

 
 
First Name:    

 
 
Last Name:    

 
 
E-mail address:    

 
 
Date: __ __ __ __ - __ __- __ __  

Form 2116 R3.0: Plasma Cell Disorders (PCD) Post-HCT Data  
Center:  CRID: 

CIBMTR Form 2116 revision 3.0  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 14 / 14